S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)
S&P 500   4,970.78 (-0.81%)
DOW   37,927.86 (+0.40%)
QQQ   416.02 (-1.75%)
AAPL   165.59 (-0.87%)
MSFT   400.44 (-0.95%)
META   482.20 (-3.91%)
GOOGL   154.01 (-1.28%)
AMZN   174.84 (-2.44%)
TSLA   148.37 (-1.04%)
NVDA   786.21 (-7.15%)
AMD   147.95 (-4.60%)
NIO   3.82 (-4.50%)
BABA   68.93 (+0.07%)
T   16.44 (+0.67%)
F   12.11 (+0.41%)
MU   107.04 (-4.37%)
GE   148.62 (-2.82%)
CGC   8.00 (+2.17%)
DIS   112.29 (-0.12%)
AMC   3.21 (+9.93%)
PFE   25.85 (+1.81%)
PYPL   62.10 (+0.00%)
XOM   119.76 (+1.05%)

Entrada Therapeutics (TRDA) Earnings Date, Estimates & Call Transcripts

$12.13
+0.22 (+1.85%)
(As of 02:14 PM ET)

Earnings Summary

Upcoming
Earnings Date
May. 8Estimated
Actual EPS
(Mar. 13)
-$0.29 Missed By -$0.22
Consensus EPS
(Mar. 13)
-$0.07
Skip Charts & View Estimated and Actual Earnings Data

TRDA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TRDA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Entrada Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.73)($0.40)($0.57)
Q2 20242($0.61)($0.42)($0.52)
Q3 20242($0.64)($0.48)($0.56)
Q4 20242($0.67)($0.52)($0.60)
FY 20248($2.65)($1.82)($2.24)
Q1 20251($0.69)($0.69)($0.69)
Q2 20251($0.72)($0.72)($0.72)
Q3 20251($0.76)($0.76)($0.76)
Q4 20251($0.66)($0.66)($0.66)
FY 20254($2.83)($2.83)($2.83)

TRDA Earnings Date and Information

Entrada Therapeutics last issued its earnings results on March 13th, 2024. The reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.22. The firm earned $41.85 million during the quarter, compared to the consensus estimate of $27.82 million. Entrada Therapeutics has generated ($0.26) earnings per share over the last year (($0.26) diluted earnings per share). Earnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share. Entrada Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.

Entrada Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/8/2024
Estimated)
------- 
3/13/2024Q4 2023($0.07)($0.29)($0.22)($0.29)$27.82 million$41.85 million
11/7/2023Q3 2023($0.55)$1.02+$1.57$1.02$16.31 million$43.74 million
8/8/2023Q2 2023($0.43)($0.78)($0.35)($0.78)$19.56 million$18.17 million
5/10/2023Q1 2023($0.77)($0.21)+$0.56($0.21)-$25.26 million
3/6/2023Q4 2022($0.83)($0.79)+$0.04($0.79)--
11/7/2022Q3 2022-($0.80)($0.80)($0.80)--
8/11/2022Q2 2022-($0.74)($0.74)($0.74)--
5/12/2022Q1 2022-($0.69)($0.69)($0.69)--
3/15/2022Q4 2021-($0.89)($0.89)($0.89)--
12/8/2021Q3 2021($0.87)($9.78)($8.91)($9.78)--

Entrada Therapeutics Earnings - Frequently Asked Questions

When is Entrada Therapeutics's earnings date?

Entrada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on TRDA's earnings history.

Did Entrada Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Entrada Therapeutics (NASDAQ:TRDA) missed the analysts' consensus estimate of ($0.07) by $0.22 with a reported earnings per share (EPS) of ($0.29). Learn more on analysts' earnings estimate vs. TRDA's actual earnings.

How much revenue does Entrada Therapeutics generate each year?

Entrada Therapeutics (NASDAQ:TRDA) has a recorded annual revenue of $129.01 million.

How much profit does Entrada Therapeutics generate each year?

Entrada Therapeutics (NASDAQ:TRDA) has a recorded net income of -$6.68 million. TRDA has generated -$0.26 earnings per share over the last four quarters.

What is Entrada Therapeutics's EPS forecast for next year?

Entrada Therapeutics's earnings are expected to decrease from ($1.54) per share to ($2.78) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:TRDA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners